Indeed, NK cells account for ~50% of the lymphocytes in the liver.4 SLAMF7 stimulates NK cell cytotoxicity as both a ligand and a receptor, and the anti-SLAMF7 agent elotuzumab is approved by the FDA for the treatment of multiple myeloma.38 HCC has low cure and survival rates,39 and among the various and complicated HCC etiologies, non-viral HCC, particularly MASH-related HCC, is unresponsive to immunotherapy with anti-PD-1 antibody.17 Therefore, the possibility that TSIs can suppress the immunosuppressive effect of TM4SF5 on NK cells has clinical implications for the treatment of HCC. This evidence concerns the gene PDCD1 and AL amyloidosis.